Table 2.
Main characteristics of the studies included in the review concerning oritavancin (arranged by publication year).
| Authors (Year) [Bibliography Reference] | Design of the Study (Country) | Pathogens | Sample size | Dosing | Outcome | |
|---|---|---|---|---|---|---|
| ABSSSI | ||||||
| Sacdal et al. (2022) [75] | Monocentric, retrospective study (USA) | NA | 51 oritavancin group vs 31 oral antibiotics group | IVD 1200 mg single dose | 16% ED revisit (vs 36%)* 12% hospitalisation rate (vs 26%)† |
|
| Dretske et al. (2021) [76] | Monocentric, retrospective study (USA) | MSSA, MRSA, Streptococcus spp. | 11 patients | IVD 1200 mg single dose | 63% clinical success | |
| Helton et al. (2020) [36] | Monocentric, retrospective study (USA) | MSSA, MRSA, Streptococcus spp. | 61 oritavancin group vs 61 vancomycin group | IVD 1200 mg single dose | 10% 30-day readmission (vs 10%)† 25% 30-day ED return (vs 29%) † |
|
| Estrada et al. (2020) [38] | Multicentric, retrospective study (USA) | NA | 115 outpatient cohort, 151 hospital discharge cohort | IVD 1200 mg single dose |
Outpatient cohort: 6% 30-days admission, 10% antibiotics within 30 days post index treatment Hospital discharge: 7% 30-days readmission |
|
| Redell et al. (2019) [39] | Multicentric, retrospective study (USA) | Not specified for all patients (MRSA, MSSA, Streptococcus pyogenes, CoNS, Enterococcus faecalis, Corynebacterium spp.) | 401 ABSSSI (440 cases) | IVD 1200 mg single dose/multiple doses (95% single dose) | 88% clinical success overall | |
| Co et al. (2018) [41] | Multicentric, retrospective study (USA) | NA | 37 ABSSSI (67 patients) | IVD 1200 mg single dose | 0% 14-days readmission | |
| Anastasio et al. (2017) [37] | Monocentric, retrospective study (USA) | In the oritavancin group: 79% MSSA, 42% MRSA, 14% E. faecalis | 59 oritavancin group vs 59 SoC group | IVD 1200 mg single dose | 90% clinical success at 5–30 days completion (vs 77%)† | |
| Corey et al. (2014) [27] | Multicentric, double-blind, randomized clinical trial (Argentina, Canada, India, Israel, Mexico, Romania, Russia, Spain, Ukraine, USA) | MSSA, MRSA, streptococci (S. anginosus, S. pyogenes, S. dysgalactiae, S. agalactiae), E. faecalis | 1019 patients: 509 oritavancin group vs 510 vancomycin | IVD 1200 mg single dose | 80% efficacy at early clinical evaluation (vs 83%) 83% efficacy at 7–14 days post therapy (vs 80%) |
|
| Infective endocarditis | ||||||
| Ahiskali et al. (2020) [44] | Monocentric, retrospective study (USA) | 1 MSSA, 1 MRSA | 2 patients | IVD 1200 mg for 1 to 2 doses | 50% cure, 50% failure (spondylodiscitis) | |
| Brownell et al. (2020) [77] | Multicentric, retrospective study (USA) | NA | 4 patients | NA | Cure | |
| Morisette et al. (2019) [78] | Multicentric, retrospective study (USA) | E. faecalis | 1 native valve endocarditis | IVD 1200 mg single dose | Lost to follow-up | |
| Terrero Salcedo et al. (2018) [43] | Monocentric case series (USA) | 2 MSSA, 2 MRSA, 1 S. pyogenes/group F Streptococcus | 5 native valve endocarditis | IVD 1200 mg once weekly for 1 to 4 doses | 60% cure 40% lost to follow-up |
|
| Stewart et al. (2018) [54] | Multicentric, retrospective study (USA) | S. agalactiae | 1 native valve endocarditis | IVD 1200 mg single dose | Failure (valve replacement surgery) | |
| Johnson et al. (2015) [42] | Case report (USA) | VRE | 1 prosthetic valve endocarditis | IVD 1200 mg every 48 hours for 3 doses, then once weekly for 7 weeks At relapse, 1200 mg twice weekly for 10 weeks after surgery |
Cure after valve replacement surgery | |
| Endovascular graft | ||||||
| Schulz et al. (2017) [61] | Case series (USA) | Staphylococcus lugdunensis | 1 patient | IVD 1200 mg once, then 800 mg weekly for 11 doses, then 1200 mg for 1 dose following 11-day interval, then 800 mg for 5 doses weekly | Improvement | |
| Sternal wound/mediastinitis | ||||||
| Schulz et al. (2017) [61] | Case series (USA) | Cutibacterium acnes | 1 patient | IVD 1200 mg once, then 800 mg weekly for 1 dose | Clinical success | |
| Bone and joint infection (including prosthetic) | ||||||
| Van Hise et al. (2020) [53] | Multicentric, retrospective study (USA) | Monomicrobial: 71,9% MRSA, 19% MSSA, 5% VR enterococci, 2% VISA | 134 acute osteomyelitis, of which 24 prosthetic osteomyelitis | IVD 1200 mg once, then 800 mg weekly for 4 to 5 doses | 80% clinical success post treatment at 6 months follow-up | |
| Nguyen et al. (2020) [79] | Case report (USA) | VS-E. faecalis | 1 PJI | IVD 1200 mg once weekly for 6 doses (following previous antibiotic therapy) | Cure at 10 months follow-up | |
| Rendell et al. (2019) [39] | Multicentric, retrospective study (USA) | Not specified for all patients (MRSA, MSSA, S. pyogenes, Bacillus spp.) | 18 osteomyelitis, 4 septic arthritis/synovitis, 3 PJI, 3 bursitis, 1 prosthetic lumbar infection | IVD 1200 mg every 6 to 14 days, for 1 to 10 doses (78% following previous antibiotic therapy) |
Osteomyelitis: 88% clinical success Joint infection (both native/prosthetic): 71% clinical success (follow-up unknown) |
|
| Chastain et al. (2019) [80] | Monocentric case series (USA) | 55% MRSA, remaining not available/sterile | 9 chronic osteomyelitis | IVD 1200 mg (no consistent time between doses, for 2 to 6 doses) | 100% Clinical cure at 6 months follow-up | |
| Dahesh et al. (2019) [56] | Case report (USA) | VRE | 1 implant-associated vertebral osteomyelitis | IVD 1200 mg weekly for 2 doses, then 800 mg weekly for 8 doses plus ampicillin | Cure at the end of treatment | |
| Co et al. (2018) [41] | Monocentric, retrospective study (USA) | NA | 8 osteomyelitis, 5 septic arthritis, 3 diabetic foot infection | NA | No readmission within 12 days | |
| Foster et al. (2018) [55] | Case report (USA) | VRE | 1 PJI | IVD 1200 mg once weekly for 6 weeks | Cure | |
| Ruggero et al. (2018) [81] | Case report (USA) | MRSA | 1 vertebral osteomyelitis | IVD 1200 mg every 2 weeks for 4 doses, then 1200 mg 1 onth later + TMP/SMX | Cure at 1 year follow-up | |
| Schulz et al. (2017) [61] | Case series (USA) | MSSA | 4 osteomyelitis |
Multiple schemes: 1200 mg once, then 800 mg weekly for 7 doses 1200 mg for 2 weekly doses 1200 mg once, then 800 mg weekly for 4 doses 1200 mg once, then 800 mg weekly for 2 doses |
Clinical success at 2 weeks follow-up | |
| Stewart et al. (2017) [54] | Case series (USA) | MSSA | 1 osteomyelitis | IVD 1200 mg single dose | Failure | |
| Delaportas et al. (2017) [82] | Case report (USA) | MSSA | 1 osteomyelitis | IVD 1200 mg every week for 6 doses | Cure at 40 weeks follow-up to | |
| Other sites infection | ||||||
| Intraabdominal infection | Schulz et al. (2017) [61] | Case series (USA) | Enterococcus spp. | 1 recurrent bacteremia in cholecystitis 1 hepatic abcess |
IVD 1200 mg 2 doses | Failure |
| Pneumonia | Schulz et al. (2017) [61] | Case series (USA) | Small colony variant MRSA | 2 patients | IVD 1200 mg 2 doses | Clinical success |
| Meningitis | Wenzler et al. (2021) [64] | Case report (USA) | VRE | 1 patient | IVD 1200 mg for 6 doses, multiple intervals | Death by other cause |
Abbreviations: ABSSSI: acute bacterial skin and skin structure infection; USA: United States of America; ED: emergency department; NA not available; IVD intravenous drip; ORI: oritavancin; CoNS: coagulase-negative staphylococci; MSSA: methicillin-sensible Staphylococcus aureus; MRSA: methicillin-resistant S. aureus; VISA: vancomycin-intermediate S. aureus; VRE: vancomycin-resistant Enterococcus faecium; VS: vancomycin-sensible; PJI: prosthetic joint infection.
*
Statistically significant;
†
Not statistically significant.